AKT1 and familial Alzheimer disease: The prominence of PI3K/AKT/mTOR pathway modulators (AS-605240, AKT Inhibitor IV/VIII) alongside neuromodulatory compounds (mizolastine, mianserin, RO 04–6790) suggests multiple therapeutic avenues for reversing astrocytic transcriptomic dysregulation in fAD.